| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2011: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2009: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Research Abstract |
PIK3CA mutation plays a critical role in the tumorigenesis and resistance of anti-cancer drugs. We evaluated whether PIK3CA mutation would contribute to resistance of docetaxel or tamoxifen in this study. First, we analyzed association between PIK3CA mutation and efficacy of docetaxel in patients who received neoadjuvant docetaxel chemotherapy, but PIK3CA mutation was not associated with sensitivity to docetaxel. Next, we sought to examine interaction between PIK3CA mutation and breast cancer outcomes in patients who are treated with adjuvant tamoxifen alone. In our homogenous dataset of patients treated with tamoxifen alone, the incidence of PIK3CA mutation was 34.1% as consistent to previous studies. Exon9 PIK3CA mutation had a trend to favorable prognosis, in contrast with Exon20 PIK3CA wild type. These two hot spot sites could be different prognostic factor. This may help stratify patients likely to benefit endocrine therapy alone, but our dataset is too small to conclude. Therefore, further studies are needed to confirm this association.
|
